Showing 2191-2200 of 3039 results for "".
- Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington Universityhttps://modernod.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/Q BioMed has announced it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity
- Pharmaceutical Executives Field Questions at US Senate Hearing Over Drug Pricinghttps://modernod.com/news/pharmaceutical-executives-field-questions-at-us-senate-hearing-over-drug-pricing/2476258/CEOs and senior executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi, and Johnson & Johnson appeared before the US Senate Finance Committee on Tuesday to testify about the high cost of drugs in the country. The executives, who continued to blame pharmacy
- LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multicenter Clinical Trial for Treating Dry AMDhttps://modernod.com/news/lumithera-receives-notice-of-award-for-2-5-million-national-eye-institute-grant-to-support-u-s-multicenter-clinical-trial-for-treating-dry-amd/2476262/LumiThera announced that it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- CEI Vision Partners Adds Virginia Eye Consultants as Fifth Partnerhttps://modernod.com/news/cei-vision-partners-adds-virginia-eye-consultants-as-fifth-partner/2476310/CEI Vision Partners (CVP), a portfolio company of Revelstoke Capital Partners LLC , a Denver-based private equity firm, has completed a partnership with Virginia Eye Consultants (VEC) , a premier multi-specialty ophthalmology group comprised of 17 providers that service the Norfolk, Virginia Beac
- MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF for Ophthalmic Diseaseshttps://modernod.com/news/manf-therapeutics-receives-notice-of-allowance-from-us-patent-trademark-office-covering-the-use-of-manf-or-cdnf-for-ophthalmic-diseases/2476184/MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, is in preclinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases. On Tuesday, the
- Riata Capital’s Acuity Eyecare Group Completes Acquisitions in Colorado and Nebraskahttps://modernod.com/news/riata-capitals-acuity-eyecare-group-completes-acquisitions-in-colorado-and-nebraska/2476208/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of leading North American eyecare groups and optometry practices, has acquired two new regional eyecare groups, totaling 18 locations: ABBA Eye Care, based in Colorado Springs, Colora
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana
- Nicox Enters Into Collaboration With Novaliq on Topical Ophthalmic Formulationshttps://modernod.com/news/nicox-enters-into-collaboration-with-novaliq-on-topical-ophthalmic-formulations/2476241/Nicox announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators. As part of this focus, Nicox has entered into a res